Organogenesis (NASDAQ:ORGO) Shares Gap Down - Time to Sell?

Shares of Organogenesis (NASDAQ:ORGO - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $4.49, but opened at $3.90. Organogenesis shares last traded at $4.14, with a volume of 1,138,044 shares traded.

Analysts Set New Price Targets

Several brokerages recently commented on ORGO. BTIG Research reiterated a "buy" rating on shares of Organogenesis in a research note on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price objective on shares of Organogenesis in a research note on Tuesday.

Organogenesis Price Performance

The company's 50 day moving average is $3.44 and its 200 day moving average is $3.89. The stock has a market cap of $562.58 million, a price-to-earnings ratio of -26.15 and a beta of 1.70.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The business had revenue of $86.69 million for the quarter, compared to analysts' expectations of $90.77 million. Sell-side analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

Insiders Place Their Bets

In other Organogenesis news, insider Lori Freedman bought 142,379 shares of the company's stock in a transaction on Thursday, June 5th. The stock was purchased at an average cost of $2.91 per share, for a total transaction of $414,322.89. Following the acquisition, the insider owned 837,437 shares of the company's stock, valued at $2,436,941.67. The trade was a 20.48% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders have bought 252,264 shares of company stock worth $725,732. Company insiders own 33.00% of the company's stock.

Hedge Funds Weigh In On Organogenesis

Hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC increased its holdings in Organogenesis by 10.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock valued at $187,000 after acquiring an additional 4,239 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Organogenesis by 29.6% during the fourth quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock worth $133,000 after buying an additional 9,464 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Organogenesis by 18.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock worth $8,925,000 after buying an additional 442,772 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Organogenesis by 53.2% during the fourth quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock worth $406,000 after buying an additional 44,051 shares in the last quarter. Finally, Prudential Financial Inc. grew its holdings in shares of Organogenesis by 92.9% during the fourth quarter. Prudential Financial Inc. now owns 237,720 shares of the company's stock worth $761,000 after buying an additional 114,500 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.